These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24462504)

  • 1. Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.
    Henry NL; Conlon A; Kidwell KM; Griffith K; Smerage JB; Schott AF; Hayes DF; Williams DA; Clauw DJ; Harte SE
    J Pain; 2014 May; 15(5):468-75. PubMed ID: 24462504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study.
    Laroche F; Coste J; Medkour T; Cottu PH; Pierga JY; Lotz JP; Beerblock K; Tournigand C; Declèves X; de Cremoux P; Bouhassira D; Perrot S
    J Pain; 2014 Mar; 15(3):293-303. PubMed ID: 24365325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
    Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
    J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Clinical Pain Locations and Pain Sensitivity in Women After Breast Cancer Surgery: Influence of Aromatase Inhibitor Therapy.
    Zhu Y; Loggia ML; Edwards RR; Flowers KM; Muñoz-Vergara DW; Partridge AH; Schreiber KL
    Clin J Pain; 2022 Dec; 38(12):721-729. PubMed ID: 36136765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
    Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
    Bhave MA; Speth KA; Kidwell KM; Lyden A; Alsamarraie C; Murphy SL; Henry NL
    Clin Breast Cancer; 2018 Apr; 18(2):168-174.e2. PubMed ID: 29361424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
    Gallicchio L; MacDonald R; Helzlsouer KJ
    J Cancer Res Clin Oncol; 2013 May; 139(5):837-43. PubMed ID: 23408333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
    Streff A; Chu-Pilli M; Stopeck A; Chalasani P
    Support Care Cancer; 2021 Jan; 29(1):187-191. PubMed ID: 32328775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
    Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
    Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
    Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
    Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
    Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
    Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
    Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
    Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
    Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
    J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
    Kadakia KC; Snyder CF; Kidwell KM; Seewald NJ; Flockhart DA; Skaar TC; Desta Z; Rae JM; Otte JL; Carpenter JS; Storniolo AM; Hayes DF; Stearns V; Henry NL
    Oncologist; 2016 May; 21(5):539-46. PubMed ID: 27009936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Moegele M; Buchholz S; Seitz S; Ortmann O
    Arch Gynecol Obstet; 2012 May; 285(5):1397-402. PubMed ID: 22212649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.